more_reports

Biotech Firm Unveils Diabetes Breakthrough in Canada

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes.
Tags: Biotechnology / Pharmaceuticals

Phase 2b Trial Data on Treatment for Inflammation Due Soon

Research Report
  ()
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Reaches MS Clinical Program Milestones

Research Report
  ()
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Co.'s New Cancer Drug Shows Promise

Research Report
  ()
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Unlocks Gene Therapy Breakthrough in Canada

  ()
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.
Tags: Biotechnology / Pharmaceuticals

Canadian Biotech Advances High-Impact DDR Programs

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy.
Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Uncovers AI Healthcare Growth Opportunity

  ()
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.
Tags: Life Sciences Tools & DiagnosticsTechnology

Data Readout Positive from Trial of New Schizophrenia Drug

Research Report
  ()
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market
Tags: Biotechnology / Pharmaceuticals

A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy.
Tags: Biotechnology / Pharmaceuticals

Treatment.com AI's Rocket Doctor Expands US Reach and Drives New Growth Through Virtual ER Innovation

  ()
Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) virtual care subsidiary, Rocket Doctor, has expanded its core virtual care services into New York and California. Separately, its virtual ER program, designed to reduce unnecessary emergency room visits, continues to demonstrate a strong impact. Over a 12-month period between 2023 and 2024, Rocket Doctor reported an 88% year-over-year increase in revenue."
Tags: Healthcare Services

Co. Poised to Begin Major New Bull Market

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy.
Tags: TechnologySpecial SituationsLife Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Centrally Positioned AI Co. Platform Designed To Transform Healthcare

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks now is an excellent time to buy or add to positions in Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA).
Tags: Life Sciences Tools & DiagnosticsTechnology

Co. Prepares to Roll Out Wound Irrigating Solution

Research Report
  ()
BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.
Tags: Biotechnology / Pharmaceuticals

Interim Data From TID Trial Are Positive

  ()
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.
Tags: Regenerative MedicineMedical Devices

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Biopharma Receives PDUFA Date for Lead Program

Research Report
  ()
This is a critical milestone for the company and significant for the space given the lack of approved therapies, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Cell Treatment for Bladder Cancer Shows Promise

Research Report
  ()
This investigative therapy is "uniquely positioned to occupy a distinct segment" within the evolving and crowded space, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biopharma Shares Efficacy Data at AUA Meeting

Research Report
  ()
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial

  ()
Clinical-stage biopharmaceutical company Protara Therapeutics Inc. (TARA:NASDAQ) announces updated results from its trials of a drug for high-risk non-muscle invasive bladder cancer (NMIBC). Read why analysts are recommending this biopharmaceutical stock.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Long-Term Cancer Breakthrough in Nevada

  ()
UroGen Pharma Ltd. (URGN:NASDAQ) unveiled nearly four years of durable response for JELMYTO in Nevada, offering a breakthrough for low-grade upper tract cancer patients. See how UroGen Pharmas breakthrough data could reshape non-surgical cancer treatments and drive future growth in the oncology sector.
Tags: Biotechnology / Pharmaceuticals